| Completed | A Study of Mavorixafor in Combination With Ibrutinib in Participants With Waldenstrom's Macroglobulinemia (WM) NCT04274738 | X4 Pharmaceuticals | Phase 1 |
| Terminated | A Study of Ulocuplumab And Ibrutinib in Symptomatic Patients With Mutated CXCR4 Waldenstrom's Macroglobulinemi NCT03225716 | Dana-Farber Cancer Institute | Phase 1 |
| Unknown | Study of Safety,Efficacy and Pharmacokinetics of CT-1530 in Patients With Relapsed or Refractory B Cell Non-Ho NCT02981745 | Centaurus Biopharma Co., Ltd. | Phase 1 / Phase 2 |
| Completed | Study of Ibrutinib in Patients With Symptomatic, Previously Untreated Waldenstrom's Macroglobulinemia, and Imp NCT02604511 | Dana-Farber Cancer Institute | Phase 2 |
| Terminated | Study of Phosphatidylinositol-3-kinase (PI3K) Inhibitor Idelalisib (GS-1101) in Waldenström Macroglobulinemia NCT02439138 | Dana-Farber Cancer Institute | Phase 2 |
| Completed | Study of High-dose Influenza Vaccine Efficacy by Repeated Dosing IN Gammopathy Patients NCT02566265 | Yale University | Phase 2 |
| Completed | Trial of Ixazomib, Dexamethasone and Rituximab in Patients With Untreated Waldenstrom's Macroglobulinemia NCT02400437 | Dana-Farber Cancer Institute | Phase 2 |
| Completed | Extension Study of IMO-8400 in Patients With Waldenström's Macroglobulinemia Who Completed Study 8400-401 NCT02363439 | Idera Pharmaceuticals, Inc. | Phase 1 / Phase 2 |
| Completed | Fase II Study With BRB for Non-Hodgkin Lymphoplasmacytic Lymphoma/Waldenstrom Macroglobulinemia's NCT02371148 | Fondazione Italiana Linfomi - ETS | Phase 2 |
| Terminated | Phase 1/2 Dose Escalation Study in Patients With Relapsed or Refractory Waldenstrom's Macroglobulinemia NCT02092909 | Idera Pharmaceuticals, Inc. | Phase 1 / Phase 2 |
| Terminated | Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignancies NCT01744912 | TG Therapeutics, Inc. | Phase 1 |
| Completed | Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lym NCT01647971 | TG Therapeutics, Inc. | Phase 1 / Phase 2 |
| Completed | Ibrutinib (PCI-32765) in Waldenstrom's Macroglobulinemia NCT01614821 | Dana-Farber Cancer Institute | Phase 2 |
| Completed | Carfilzomib, Rituximab and Dexamethasone in Waldenstrom's Macroglobulinemia NCT01470196 | Dana-Farber Cancer Institute | Phase 2 |
| Terminated | Pomalidomide, Dexamethasone and Rituximab in Waldenstrom's Macroglobulinemia NCT01078974 | Steven P. Treon, MD, PhD | Phase 1 |
| Terminated | Everolimus, Bortezomib and/or Rituximab in Patients With Relapsed/Refractory Waldenstrom's Macroglobulinemia NCT01125293 | Dana-Farber Cancer Institute | Phase 1 / Phase 2 |
| Active Not Recruiting | Questionnaire and Tissue Banking For Multiple Myeloma, Waldenstrom Macroglobulinemia and Related Disorders NCT01177527 | Dana-Farber Cancer Institute | — |
| Completed | Everolimus (RAD001) in Primary Therapy of Waldenstrom's Macroglobulinemia NCT00976248 | Dana-Farber Cancer Institute | Phase 2 |
| Completed | LBH589 in Relapsed or Relapsed and Refractory Waldenstrom's Macroglobulinemia NCT00936611 | Dana-Farber Cancer Institute | Phase 2 |
| Completed | A Phase 1 Dose Escalation Study of TAK-901 in Subjects With Advanced Hematologic Malignancies NCT00807677 | Millennium Pharmaceuticals, Inc. | Phase 1 |
| Completed | Study of MLN8237 in Participants With Advanced Hematological Malignancies NCT00697346 | Millennium Pharmaceuticals, Inc. | Phase 1 |
| Completed | A Study for Patients That Have Been Previously Been Treated in Waldenstrom's Macroglobulinemia or Multiple Mye NCT00718419 | Eli Lilly and Company | Phase 2 |
| Terminated | Simvastatin in Waldenstrom's Macroglobulinemia NCT00575965 | Dana-Farber Cancer Institute | Phase 2 |
| Completed | Study of Pralatrexate & Gemcitabine With B12 & Folic Acid to Treat Relapsed/Refractory Lymphoproliferative Mal NCT00481871 | Acrotech Biopharma Inc. | Phase 1 / Phase 2 |
| Completed | Bortezomib, Dexamethasone, and Rituximab in Previously Untreated Patients With Waldenstrom's Macroglobulinemia NCT01046006 | Meletios A. Dimopoulos | Phase 2 |
| Completed | Perifosine in Patients With Relapsed/Refractory Waldenstrom's Macroglobulinemia NCT00422656 | Dana-Farber Cancer Institute | Phase 2 |
| Completed | Combination Bortezomib and Rituximab in Patients With Waldenstrom's Macroglobulinemia (WM) NCT00422799 | Dana-Farber Cancer Institute | Phase 2 |
| Active Not Recruiting | Bortezomib and Rituximab for Patients With Waldenstrom's Macroglobulinemia NCT00492050 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Trial of AVN-944 in Patients With Advanced Hematologic Malignancies NCT00273936 | Vertex Pharmaceuticals Incorporated | Phase 1 |
| Completed | Study of the Combination of Bortezomib, Dexamethasone, and Rituximab in Patients With Waldenstroms Macroglobul NCT00250926 | Dana-Farber Cancer Institute | Phase 2 |
| Completed | Sildenafil Citrate in Waldenstrom's Macroglobulinemia NCT00165295 | Dana-Farber Cancer Institute | Phase 2 |
| Completed | Safety Study of the Proteasome Inhibitor PR-171 (Carfilzomib for Injection) in Patients With Hematological Mal NCT00150462 | Amgen | Phase 1 |
| Terminated | CC-5013 (Lenalidomide) and Rituximab in Waldenstrom's Macroglobulinemia NCT00142168 | Dana-Farber Cancer Institute | Phase 2 |
| Completed | Bortezomib (Velcade) in Waldenstrom's Macroglobulinemia NCT00142129 | Dana-Farber Cancer Institute | Phase 2 |
| Completed | S0309, Repository: Blood/Bone Marrow From Pts. With Myeloma, WM, Amyloidosis, or MGUS. NCT00919139 | SWOG Cancer Research Network | — |
| Completed | Thalidomide and Rituximab in Waldenstrom's Macroglobulinemia NCT00142116 | Steven P. Treon, MD, PhD | Phase 2 |
| Completed | Phase II Study of Campath-1H Antibody to Treat Waldenstrom's Macroglobulinemia NCT00142181 | Dana-Farber Cancer Institute | Phase 2 |
| Completed | Correlation of FC Gamma RIIIA Receptor Response in Patients With Waldenstrom's Macroglobulinemia NCT00142155 | Dana-Farber Cancer Institute | N/A |
| Completed | Low-Intensity Preparation and Allogeneic Transplant in Patients With Cancers of the Blood NCT00146055 | University of Michigan Rogel Cancer Center | Phase 2 |